dbo:abstract
|
- Rutecarpine or rutaecarpine is a COX-2 inhibitor isolated from Tetradium ruticarpum. It is claimed as one of the non-basic alkaloids. In contrast to synthetic COX-2 inhibitors like Etoricoxib and Celecoxib Rutecarpine does not show their negative effects on the cardiovascular system; in fact it even does compensate for the adverse effects usually caused by COX-2 inhibition. Microsome studies suggest that rutaecarpine may be at least a weak inhibitor of CYP1A2, CYP2C9, CYP2C19, CYP2E1, and CYP3A4 enzymes. At the same time, it is believed to be a rather strong inducer of the CYP1A2 and CYP1A1 enzymes. Rutecarpine has been shown to decrease the overall bioavailability of caffeine in rats by to 80%. Caffeine metabolism in rats given rutecarpine is modified greatly, likely through the induction of both the CYP1A2 and CYP2E1 enzymes. A natural product, rutecarpine can be purchased legally online, where it is sold as a "decafeineator". The long-term safety of rutecarpine supplementation has not been established. Rutecarpine metabolism is complex and proceeds along several routes, primarily involving the addition of a single hydroxyl group by CYP3A4. Six monohydroxylated and four dihydroxylated metabolites have been identified. To a much lesser extent rutecarpine may also be metabolized by CYP2C9 and CYP1A2, according to liver microsome studies. (en)
|
dbo:iupacName
|
- 8,13-Hydroindolo[2′,3′:3,4]pyrido[2,1-b]quinazolin-5(7H)-one (en)
|
dbo:thumbnail
| |
dbo:wikiPageID
| |
dbo:wikiPageLength
|
- 6397 (xsd:nonNegativeInteger)
|
dbo:wikiPageRevisionID
| |
dbo:wikiPageWikiLink
| |
dbp:imagefile
| |
dbp:imagesize
| |
dbp:pin
| |
dbp:wikiPageUsesTemplate
| |
dcterms:subject
| |
rdf:type
| |
rdfs:comment
|
- Rutecarpine or rutaecarpine is a COX-2 inhibitor isolated from Tetradium ruticarpum. It is claimed as one of the non-basic alkaloids. In contrast to synthetic COX-2 inhibitors like Etoricoxib and Celecoxib Rutecarpine does not show their negative effects on the cardiovascular system; in fact it even does compensate for the adverse effects usually caused by COX-2 inhibition. (en)
|
rdfs:label
| |
owl:sameAs
| |
prov:wasDerivedFrom
| |
foaf:depiction
| |
foaf:isPrimaryTopicOf
| |
is dbo:wikiPageRedirects
of | |
is dbo:wikiPageWikiLink
of | |
is foaf:primaryTopic
of | |